Why Wegovy might not be working the second time — and what to do about it

You stopped, you restarted, and now it feels like nothing is happening

Picture this: your first Wegovy course went reasonably well. You lost a meaningful amount of weight, the nausea settled after a few weeks, and you eventually stopped, maybe because supply dried up, maybe because life intervened. Now you are back on it and three or four weeks in, the appetite suppression you remember is barely there. The pen is in the fridge door, the doses are going in on time, yet the scales are not moving the way they did before.

The most common reason is straightforward: retitration. Wegovy's licensed schedule restarts at 0.25 mg regardless of where you finished last time. At that dose, the pharmacological effect on appetite is modest, the dose exists to let your gut adjust, not to drive weight loss. Many people expect to pick up where they left off and are caught off guard when they do not. If you are only a few weeks into a restart, the honest answer is that you may simply not be at a therapeutic dose yet. The timeline for Wegovy to take effect is typically counted from reaching the maintenance dose, not from the first injection.

There is also a subtler issue. During your first course, your body adapted to lower circulating levels of the gut hormone GLP-1, semaglutide mimics this hormone to slow stomach emptying and signal fullness. After stopping, some of those adaptations persist for a period, meaning the same low dose that felt noticeable the first time may now feel weaker. This is not a sign that semaglutide is permanently less effective for you; it tends to resolve as the dose increases.

What the evidence actually says about restarting weight-loss treatment

Clinical data on weight regain after stopping semaglutide are clear and worth knowing. The STEP 1 extension study, published in the New England Journal of Medicine, showed that participants who stopped semaglutide 2.4 mg after 68 weeks regained most of the lost weight within a year. This tells us two things: the medicine was working during the active course, and bodyweight has a strong biological pull back toward its previous setpoint once treatment stops. Feeling heavier at the start of a second course is therefore expected, not a sign you have somehow become resistant.

What the evidence does not yet resolve cleanly is whether the rate of loss on a second course is meaningfully slower than the first, or whether it simply feels that way because the retitration phase is longer relative to the total time on treatment. Clinicians tend to see both patterns. Some patients move through the dose steps quickly and reach their previous results; others find the appetite suppression takes longer to re-establish and benefit from a slightly extended titration window. That judgement belongs with your prescriber.

If you are specifically wondering about results during the early weeks, the second-week Wegovy page covers what most people notice at that point and what is within normal range. The NHS medicines guidance on semaglutide also sets out what to expect during treatment and when to seek advice.

When a slow restart might signal something worth investigating

There is a difference between a restart that feels slow because you are still titrating and one that feels slow because something else is going on. If you have reached 1.7 mg or 2.4 mg and still notice no meaningful reduction in appetite or weight after six weeks at that dose, that is a conversation for your prescriber rather than a waiting game. A few things are worth checking. Storage matters more than people realise: semaglutide must be kept refrigerated between 2–8°C, and a pen that has spent time outside that range may be degraded without looking any different. Gut conditions, thyroid function and certain medicines can all blunt the response.

It is also worth being honest about what changed between your first and second courses. Lifestyle factors (sleep quality, stress levels, ultra-processed food intake) interact with GLP-1 medicines in ways that are increasingly well-documented. The medicine reduces appetite; it does not override every other driver of weight. If those factors have shifted since your first course, the treatment alone will not compensate.

People sometimes ask whether switching medicine might make more sense than persisting. That is a legitimate clinical question. If you want to understand what options look like, the Wegovy overview and the broader weight-loss treatment page set out the licensed choices in the UK, including how tirzepatide compares as an alternative. On the cost side, the Wegovy price comparison page gives honest context on private treatment pricing.

The practical checklist before your next prescriber conversation

Going into a consultation with specific information makes it considerably more useful. Note how many weeks you have been back on treatment, which dose you are currently on, where you are storing the pen and for how long, and whether you have noticed any side effects. If appetite suppression was noticeable at any point during this restart, even briefly, say so, it matters clinically.

Also think about the gap between courses: how long were you off treatment, and roughly how much weight returned? A prescriber can use that timeline to form a view on whether a different approach to the restart (including pace of titration) might be more effective. If the broader question is whether Wegovy is the right fit for you at all, reading about what to do when Wegovy is not working covers that in more detail, as does the page on Wegovy not working more generally.

These are prescription-only medicines requiring ongoing clinical assessment. If you have not yet spoken to a prescriber about your restart, check your eligibility with our clinical team, a GPhC-registered prescriber reviews every consultation personally, the same day.